Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06524973 · ClinicalTrials.gov registry record · NA

Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers

A NA study of Metastatic Pancreatic Adenocarcinoma, sponsored by City of Hope Medical Center.

Recruiting
Registry status
NA
Development phase
136
Enrollment target
20
Study locations

NCT06524973: Recruiting NA study of Metastatic Pancreatic Adenocarcinoma, sponsored by City of Hope Medical Center.

NCT06524973 is a NA study of Metastatic Pancreatic Adenocarcinoma that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 136 participants, above the 86-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (58% higher). The trial reports 20 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06524973, a NA study of Metastatic Pancreatic Adenocarcinoma, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
NA
Development phase
136 participants
Enrollment target
20
Study locations

Study Summary

This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative impact on quality of life. Patients and their families have unmet needs during treatment, including a lack of quality of life programs that offer support to patients. Supporting patients and families on managing the physical symptoms, emotional well-being, social well-being and spiritual well-being with telehealth self-management coaching sessions may help improve quality of life, manage symptoms from treatment, and support families in their role as caregivers during treatment.

Primary Outcome

Patient reported quality of life will be assessed by the Functional Assessment of Cancer Therapy- Hepatobiliary (FACT-Hep) quality of life score. The primary analysis will be a treatment group comparison of the QOL at 3 months via linear regression model, with adjustment for baseline FACT-Hep score and stratification factors. Robust standard errors will be estimated via generalized estimating equations to adjust for correlation between repeated outcome measures. The dependent variables will be t

Interventions

  • OTHER Questionnaire Administration
  • OTHER Best Practice
  • OTHER Counseling
  • OTHER Telemedicine
  • OTHER Inrweview

Study Locations (20)

California

  • City of Hope at Arcadia - Arcadia
  • City of Hope Corona - Corona
  • City of Hope at Duarte - Duarte
  • City of Hope Comprehensive Cancer Center - Duarte
  • City of Hope at Glendale - Glendale
  • City of Hope at Glendora - Glendora
  • City of Hope Seacliff - Huntington Beach
  • City of Hope at Irvine Lennar - Irvine
  • City of Hope at Irvine Sand Canyon - Irvine
  • City of Hope Antelope Valley - Lancaster
  • City of Hope at Long Beach Worsham - Long Beach
  • City of Hope at Long Beach Elm - Long Beach
  • City of Hope Mission Hills - Mission Hills
  • City of Hope at Newport Beach Fashion Island - Newport Beach
  • City of Hope at Palmdale - Palmdale
  • City of Hope - Santa Clarita - Santa Clarita
  • City of Hope at Simi Valley - Simi Valley
  • City of Hope South Pasadena - South Pasadena
  • City of Hope at Thousand Oaks - Thousand Oaks
  • City of Hope South Bay - Torrance

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2024-10-07
Est. Completion 2027-05-03
Phase NA
City of Hope Medical Center

582 total trials

What NCT06524973 shows while recruiting

NCT06524973 is an interventional study that assigns participants to a tested intervention. The registered 136 participants enrollment target is mid-sized for trials with a published cap, above the 86-participant average among 37 other Metastatic Pancreatic Adenocarcinoma trials with a reported enrollment target (58% higher).

The record links to 1 condition, with Metastatic Pancreatic Adenocarcinoma appearing as the primary indexed condition, and to 5 interventions - of which Questionnaire Administration is the first listed.

NCT06524973 names 20 study sites across 1 states, led by California.

Frequently Asked Questions

What is clinical trial NCT06524973 about?

NCT06524973 is a clinical study titled "Telehealth Self-Management Coaching Sessions to Improve Quality of Life in Pancreatic Cancer Survivors and Their Family Care Givers". This clinical trial evaluates the impact of telehealth self-management coaching sessions on quality of life in pancreatic cancer survivors and their family care givers (FCGs). Patients with pancreatic cancer experience many symptoms because of the disease and treatment, which can have a negative imp...

What is the current status of trial NCT06524973?

This trial is currently recruiting. It is a NA study. The enrollment target is 136 participants. The study started on 2024-10-07. Estimated completion is 2027-05-03.

What conditions does trial NCT06524973 study?

This clinical trial studies the following conditions: Metastatic Pancreatic Adenocarcinoma.

What interventions are being tested in trial NCT06524973?

The interventions under investigation include: Questionnaire Administration (OTHER), Best Practice (OTHER), Counseling (OTHER), Telemedicine (OTHER), Inrweview (OTHER).

Who is sponsoring clinical trial NCT06524973?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06524973 being conducted?

This trial has 20 study locations across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Metastatic Pancreatic Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06524973's enrollment target sits among peer trials

136 5th of 37 higher than 33 of 37 other Metastatic Pancreatic Adenocarcinoma trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Metastatic Pancreatic Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01555892 · 136 participants · Phase 1

    Cytotoxic T-Lymphocytes for EBV-positive Lymphoma, GRALE

  • NCT03216525 · 136 participants · Phase 3

    Alvimopan Versus Placebo in Patients Undergoing Radical Cystectomy on an Enhanced Recovery Protocol

  • NCT04476901 · 136 participants · Phase 2

    Administration of Allogeneic-MSC in Patients With Non-Ischemic Dilated Cardiomyopathy

  • NCT04603898 · 136 participants · NA

    Oxalate Formation From Ascorbic Acid

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06524973, the US trial registry maintained by the National Library of Medicine. NCT06524973 (mid enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.